drugset / Trial / NCT02452983
Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This study will investigate the effects of sertraline in people with low-risk myelodysplastic syndrome (MDS). It is hoped that sertraline will decrease disease progression and reduce the need for blood transfusions.
Timeline
- Start
- 2015-05
- Primary completion
- 2020-11
- Completion
- 2020-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sertraline | Small molecule | 100 mg | Oral |